Testimony and LettersB. Douglas Hoey, Letter to the Office of Management and Budget on PBMs help increase drug prices, June 27, 2017
David Balto, Testimony before the California Senate Committee on Business, Profession and Economic Development in support of PBM reform, March 20, 2017 Jon Roth, Exec. Dir. Cal. Pharmacists Association, Testimony before the California Senate Committee on Business, Profession and Economic Development in support of PBM reform, March 20, 2017 David Balto, Testimony before the North Dakota House of Representatives in support of PBM reform bills, March 20, 2017 David Balto and Brad Wasser, Letter to the Hawaii Senate on SB 1158, a bill relating to state registration of PBMs, February 10, 2017 David Balto, Statement testimony before the House Oversight and Government Reform Committee on Developments in the Prescription Drug Market, February 4, 2016 David Balto, Testimony before the House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law on the state of competition in the Pharmacy Benefits Manager and Pharmacy Marketplaces, November 17, 2015 Lynn Quincy, Consumers Union, Testimony before the Subcommittee on Regulatory Reform, Commercial and Antitrust Law, November 17, 2015 David Balto, Comments to the FTC/DOJ Healthcare Workshop discussing the effects of PBMs' restrictive pharmacy networks on patients and specialty pharmacies, April 30, 2015. FTC Commissioner Julie Brill, Letter to the ERISA Advisory Council of the Department of Labor disputing FTC Staff opinion that PBM market is competitive, August 19, 2014 David Balto, Testimony before the Department of Labor on the benefits of PBM transparency, June 19, 2014 Lynn Quincy, Consumers Union, Testimony before the Department of Labor on the benefits of PBM transparency, June 19, 2014 Randy DeFrehn, National Coordinating Committee for Multi-employer Plans, Testimony before the Department of Labor on the benefits of PBM transparency, June 19, 2014 Joe Baker, Testimony before the Energy & Commerce Committee, Subcommittee on Health, February 26, 2014 David Balto, Letter to the Hawaii Legislature on anti-mail order legislation, April 12, 2013 David Balto, Testimony before the North Dakota Legislature on PBM MAC legislation, March 25, 2013 David Balto, Letter to New York Governor Andrew Cuomo in Support of a Bill Prohibiting Mandatory Mail Order, October 2011 David Balto, Testimony before the Department of Labor on the benefits of PBM transparency, December 2010 Zach French, Testimony of the National Community Pharmacists Association on the benefits of PBM transparency, December 2010 David Balto, Testimony before the Ohio Senate Insurance, Commerce and Labor Committee addressing the increasing problem of the ownership of PBMs by pharmacy chains, February 2010 Larry McNeely, Testimony of U.S. P.I.R.G before the House Committee on Oversight and Government reform addressing how government regulation of PBMs can lead to better drug cost controls in the Federal Health Employees Benefits Program, February 2010 Sharon Treat, Letter to Speaker of the House, Nancy Pelosi, to support H.R. 3200, August 2009 David Balto, Testimony before the Consumer Protection, Product Safety and Insurance subcommittee of the Senate Committee on Commerce, Science and Transportation on "Competition in the Health Care Marketplace--The Effects of Regulatory Neglect on Health Care Consumers", July 2009 David Balto, Testimony before the United States House of Representatives Committee on the Judiciary, Antitrust Task Force. "The Impact of Our Antitrust Laws on Community Pharmacies and their Patients", October 2007 David Balto, Letter to the Honorable Secretary Donald Clark, comments on the Generic Drug Study, June 2006 David Balto, Letter to Chairman Duane Mutch, comments on H.B. 1332, November 2005 |